
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd is positioned favorably due to a significant increase in its equipment utilization rate, exceeding 50% since the introduction of strategic investments. The company is capitalizing on recent FDA approvals, particularly with the Neurolief Proliv™Rx device, which enhances its revenue potential and elevates its overall valuation metrics. Furthermore, BrainsWay's growing acceptance of pay-per-use models and its expanding presence among neurologist prescribers indicate strong prospects for accelerated revenue growth in the evolving medtech landscape.
Bears say
BrainsWay Ltd faces several fundamental risks that contribute to a negative outlook on its stock. These risks include a slower-than-projected uptake of its Deep TMS systems, which could hinder revenue growth, as well as challenges in expanding reimbursement and market access that may limit patient adoption. Additionally, the company's inability to advance into other indications and potential long-term dilution risk raise concerns about its financial stability and market position.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares